Low absolute bioavailability of oral naloxone in healthy subjects.

  title={Low absolute bioavailability of oral naloxone in healthy subjects.},
  author={Kevin J. Smith and Michael Hopp and Gill E Mundin and Simon Bond and P. K. Bailey and Jo Woodward and David Bell},
  journal={International journal of clinical pharmacology and therapeutics},
  volume={50 5},
OBJECTIVE To determine the absolute bioavailability of naloxone from oral doses ranging from 5 mg to 120 mg. MATERIALS AND METHODS In this open-label study, 28 healthy subjects received naloxone 1 mg (0.4 mg/ml) as an intravenous infusion (reference treatment), and the following oral doses as prolonged release (PR) naloxone tablets: 5 mg, 20 mg, 40 mg, 80 mg and 120 mg. The pharmacokinetic characteristics of 40 mg administered per rectum were also investigated. Each subject received five of… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS